PEGVALIASE PQPZ

N/A

Manufactured by BioMarin Pharmaceutical Inc.

14,737 FDA adverse event reports analyzed

Last updated: 2026-04-14

About PEGVALIASE PQPZ

PEGVALIASE PQPZ is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by BioMarin Pharmaceutical Inc.. The most commonly reported adverse reactions for PEGVALIASE PQPZ include ARTHRALGIA, INJECTION SITE REACTION, INJECTION SITE ERYTHEMA, INJECTION SITE SWELLING, RASH. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for PEGVALIASE PQPZ.

Top Adverse Reactions

ARTHRALGIA1,316 reports
INJECTION SITE REACTION855 reports
INJECTION SITE ERYTHEMA690 reports
INJECTION SITE SWELLING510 reports
RASH473 reports
URTICARIA471 reports
HEADACHE417 reports
INJECTION SITE PAIN397 reports
FATIGUE360 reports
INJECTION SITE PRURITUS339 reports
HYPERSENSITIVITY327 reports
PRURITUS318 reports
DIZZINESS307 reports
DYSPNOEA304 reports
ANAPHYLACTIC REACTION300 reports
NAUSEA295 reports
OFF LABEL USE292 reports
VOMITING224 reports
PYREXIA217 reports
INJECTION SITE RASH202 reports
INJECTION SITE BRUISING199 reports
PAIN199 reports
MATERNAL EXPOSURE DURING PREGNANCY189 reports
AMINO ACID LEVEL DECREASED186 reports
ALOPECIA169 reports
COVID 19162 reports
ERYTHEMA162 reports
CHEST DISCOMFORT154 reports
CHILLS150 reports
ANXIETY149 reports
PAIN IN EXTREMITY147 reports
CHEST PAIN140 reports
DIARRHOEA138 reports
COUGH134 reports
THROAT TIGHTNESS132 reports
BACK PAIN129 reports
AMINO ACID LEVEL INCREASED124 reports
PERIPHERAL SWELLING105 reports
ABDOMINAL PAIN UPPER97 reports
FLUSHING94 reports
INJECTION SITE INDURATION92 reports
NASOPHARYNGITIS91 reports
INJECTION SITE URTICARIA87 reports
MYALGIA86 reports
ABDOMINAL PAIN85 reports
INJECTION SITE WARMTH85 reports
SWELLING FACE84 reports
HEART RATE INCREASED83 reports
DECREASED APPETITE82 reports
OROPHARYNGEAL PAIN79 reports
ASTHENIA76 reports
SWELLING75 reports
PALPITATIONS74 reports
DRUG INEFFECTIVE73 reports
TREMOR69 reports
HYPOAESTHESIA67 reports
PARAESTHESIA67 reports
FEELING HOT66 reports
JOINT SWELLING65 reports
INFLUENZA64 reports
MIGRAINE64 reports
FEELING ABNORMAL57 reports
GAIT DISTURBANCE52 reports
DISTURBANCE IN ATTENTION51 reports
HYPERHIDROSIS51 reports
PHARYNGEAL SWELLING49 reports
WEIGHT INCREASED49 reports
INJECTION SITE MASS48 reports
NASAL CONGESTION48 reports
ABDOMINAL DISCOMFORT47 reports
DEPRESSION47 reports
PANIC ATTACK45 reports
INJECTION SITE HAEMORRHAGE43 reports
LYMPHADENOPATHY43 reports
MALAISE43 reports
MUSCLE SPASMS43 reports
RASH PRURITIC43 reports
THROAT IRRITATION43 reports
WEIGHT DECREASED43 reports
LIP SWELLING41 reports
INJECTION SITE SCAR40 reports
TACHYCARDIA39 reports
DYSPEPSIA38 reports
RASH ERYTHEMATOUS37 reports
FALL35 reports
LOSS OF CONSCIOUSNESS35 reports
INSOMNIA34 reports
NEPHROLITHIASIS34 reports
SARS COV 2 TEST POSITIVE34 reports
SINUSITIS33 reports
CONFUSIONAL STATE32 reports
PARAESTHESIA ORAL32 reports
INJECTION SITE IRRITATION31 reports
SEIZURE31 reports
SWOLLEN TONGUE31 reports
WHEEZING31 reports
DYSPHAGIA30 reports
ABORTION SPONTANEOUS29 reports
ARTHRITIS29 reports
PAIN IN JAW29 reports

Report Outcomes

Out of 7,592 classified reports for PEGVALIASE PQPZ:

Serious 15.8%Non-Serious 84.2%

The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.

Demographics Breakdown

Reports by Sex

Female2,504 (61.2%)
Male1,588 (38.8%)

Reports by Age

Age 18168 reports
Age 20109 reports
Age 19106 reports
Age 2182 reports
Age 3382 reports
Age 2380 reports
Age 3580 reports
Age 2578 reports
Age 3972 reports
Age 2271 reports
Age 2470 reports
Age 2770 reports
Age 2668 reports
Age 3668 reports
Age 2866 reports
Age 3863 reports
Age 3462 reports
Age 2959 reports
Age 3059 reports
Age 3758 reports

Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.

Frequently Asked Questions

How many FDA adverse event reports are associated with PEGVALIASE PQPZ?

This profile reflects 14,737 FDA FAERS reports that mention PEGVALIASE PQPZ. Reporting is voluntary and does not prove that the drug caused any listed event.

Which adverse reactions are most often listed for PEGVALIASE PQPZ?

Frequently reported terms in FAERS include ARTHRALGIA, INJECTION SITE REACTION, INJECTION SITE ERYTHEMA, INJECTION SITE SWELLING, RASH, URTICARIA. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.

Who manufactures PEGVALIASE PQPZ?

Labeling and FAERS entries often list BioMarin Pharmaceutical Inc. in connection with PEGVALIASE PQPZ. Always verify the specific product and NDC with your pharmacist.

Important Disclaimer: This content is generated by AI analysis of FDA adverse event reports and is provided for informational purposes only. It is not medical advice. Adverse event reports submitted to the FDA do not prove that a medication caused the reported side effect. Always consult your healthcare provider before starting, stopping, or changing any medication. If you experience a serious side effect, contact your doctor or call 911 immediately.